KOLON LIFE SCIENCE Inc. Logo

KOLON LIFE SCIENCE Inc.

Develops cell/gene therapies and manufactures APIs and specialty chemicals.

102940 | KO

Overview

Corporate Details

ISIN(s):
KR7102940004
LEI:
Country:
South Korea
Address:
서울특별시 강서구 마곡동로 110 코오롱 One&Only 타워, 서울특별시

Description

KOLON LIFE SCIENCE Inc. is a company operating through two primary business divisions: Bio and Chemical. The Bio division is a clinical-stage biotechnology unit focused on developing novel cell and gene therapies, with a pipeline that includes treatments for neuropathic pain and oncolytic virus therapies for cancer. The Chemical division develops, manufactures, and sells Active Pharmaceutical Ingredients (APIs), specialty chemicals, antimicrobials, and water treatment solutions. The company leverages its expertise in both biotechnology and chemical manufacturing to provide advanced healthcare and environmental products.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-08-29 00:00
대규모기업집단현황공시[분기별공시(개별회사용)]
Korean 13.6 KB
2024-08-14 00:00
반기보고서 (2024.06)
Korean 1.6 MB
2024-08-13 00:00
지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항
Korean 10.7 KB
2024-06-28 00:00
기타시장안내 (업종변경 안내)
Korean 4.7 KB
2024-06-26 00:00
[기재정정]특수관계인으로부터받은담보
Korean 9.2 KB
2024-06-26 00:00
투자판단관련주요경영사항(임상시험결과) (요천추 신경근병증 통증 치료제 KLS-2031의 미국 FDA 1/2a상 임상시험…
Korean 14.7 KB
2024-06-25 00:00
주식등의대량보유상황보고서(일반)
Korean 82.4 KB
2024-06-25 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.8 KB
2024-06-25 00:00
주식등의대량보유상황보고서(약식)
Korean 55.4 KB
2024-06-20 00:00
증권발행결과(자율공시) (제3자배정 유상증자)
Korean 5.6 KB
2024-06-20 00:00
전환가액의조정 (제2회차)
Korean 14.1 KB
2024-06-20 00:00
전환가액의조정 (제3회차)
Korean 14.2 KB
2024-06-19 00:00
재해발생
Korean 6.0 KB
2024-06-13 00:00
주요사항보고서(유상증자결정)
Korean 31.2 KB
2024-05-31 00:00
대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]
Korean 150.7 KB

Automate Your Workflow. Get a real-time feed of all KOLON LIFE SCIENCE Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KOLON LIFE SCIENCE Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KOLON LIFE SCIENCE Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.